-
Something wrong with this record ?
Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA)
C. Barinka, J. Ptacek, A. Richter, Z. Novakova, V. Morath, A. Skerra,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1996 to 1 year ago
Open Access Digital Library
from 1996-01-01
Medline Complete (EBSCOhost)
from 2004-01-01 to 1 year ago
- MeSH
- Antigens, Surface chemistry metabolism MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Glutamate Carboxypeptidase II chemistry metabolism MeSH
- Humans MeSH
- Lipocalins genetics metabolism MeSH
- Models, Molecular MeSH
- Molecular Sequence Data MeSH
- Mutation MeSH
- Protein Engineering * MeSH
- Amino Acid Sequence MeSH
- Protein Structure, Tertiary MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Although prostate carcinoma (PCa) is by far the most commonly diagnosed neoplasia in men, corresponding diagnostic and therapeutic modalities have limited efficacy at present. Anticalins comprise a novel class of binding proteins based on a non-immunoglobulin scaffold that can be engineered to specifically address molecular targets of interest. Here we report the selection and characterization of Anticalins that recognize human prostate-specific membrane antigen (PSMA), a membrane-tethered metallopeptidase constituting a disease-related target for imaging and therapy of PCa as well as solid malignancies in general. We used a randomized lipocalin library based on the human lipocalin 2 (Lcn2) scaffold together with phage display and ELISA screening to select PSMA-specific variants. Five Anticalin candidates from the original panning were expressed in Escherichia coli as soluble monomeric proteins, revealing affinities toward PSMA down to the low nanomolar range. Binding characteristics of the most promising candidate were further improved via affinity maturation by applying error-prone PCR followed by selection via phage display as well as bacterial surface display under more stringent conditions. In BIAcore measurements, the dissociation constant of the best Anticalin was determined as ∼500 pM, with a substantially improved dissociation rate compared with the first-generation candidate. Finally, immunofluorescence microscopy revealed specific staining of PSMA-positive tumor cell lines while flow cytometric analysis confirmed the ability of the selected Anticalins to detect PSMA on live cells. Taken together, Anticalins resulting from this study offer a viable alternative to antibody-based PSMA binders for biomedical applications, including in vivo imaging of PCa or neovasculature of solid tumors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000587
- 003
- CZ-PrNML
- 005
- 20170112114346.0
- 007
- ta
- 008
- 170103s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/protein/gzv065 $2 doi
- 024 7_
- $a 10.1093/protein/gzv065 $2 doi
- 035 __
- $a (PubMed)26802163
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Barinka, Cyril $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic cyril.barinka@ibt.cas.cz skerra@tum.de.
- 245 10
- $a Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA) / $c C. Barinka, J. Ptacek, A. Richter, Z. Novakova, V. Morath, A. Skerra,
- 520 9_
- $a Although prostate carcinoma (PCa) is by far the most commonly diagnosed neoplasia in men, corresponding diagnostic and therapeutic modalities have limited efficacy at present. Anticalins comprise a novel class of binding proteins based on a non-immunoglobulin scaffold that can be engineered to specifically address molecular targets of interest. Here we report the selection and characterization of Anticalins that recognize human prostate-specific membrane antigen (PSMA), a membrane-tethered metallopeptidase constituting a disease-related target for imaging and therapy of PCa as well as solid malignancies in general. We used a randomized lipocalin library based on the human lipocalin 2 (Lcn2) scaffold together with phage display and ELISA screening to select PSMA-specific variants. Five Anticalin candidates from the original panning were expressed in Escherichia coli as soluble monomeric proteins, revealing affinities toward PSMA down to the low nanomolar range. Binding characteristics of the most promising candidate were further improved via affinity maturation by applying error-prone PCR followed by selection via phage display as well as bacterial surface display under more stringent conditions. In BIAcore measurements, the dissociation constant of the best Anticalin was determined as ∼500 pM, with a substantially improved dissociation rate compared with the first-generation candidate. Finally, immunofluorescence microscopy revealed specific staining of PSMA-positive tumor cell lines while flow cytometric analysis confirmed the ability of the selected Anticalins to detect PSMA on live cells. Taken together, Anticalins resulting from this study offer a viable alternative to antibody-based PSMA binders for biomedical applications, including in vivo imaging of PCa or neovasculature of solid tumors.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a antigeny povrchové $x chemie $x metabolismus $7 D000954
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a glutamátkarboxypeptidasa II $x chemie $x metabolismus $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lipokaliny $x genetika $x metabolismus $7 D054834
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární sekvence - údaje $7 D008969
- 650 _2
- $a mutace $7 D009154
- 650 12
- $a proteinové inženýrství $7 D015202
- 650 _2
- $a terciární struktura proteinů $7 D017434
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ptacek, Jakub $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic Department of Biochemistry, Faculty of Natural Science, Charles University, Albertov 6, Prague 2, Czech Republic.
- 700 1_
- $a Richter, Antonia $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany.
- 700 1_
- $a Novakova, Zora $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic.
- 700 1_
- $a Morath, Volker $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany.
- 700 1_
- $a Skerra, Arne $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany cyril.barinka@ibt.cas.cz skerra@tum.de.
- 773 0_
- $w MED00008154 $t Protein engineering, design & selection PEDS $x 1741-0134 $g Roč. 29, č. 3 (2016), s. 105-15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26802163 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170112114445 $b ABA008
- 999 __
- $a ok $b bmc $g 1179727 $s 961154
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 29 $c 3 $d 105-15 $e 20160121 $i 1741-0134 $m Protein engineering, design & selection $n Protein Eng Des Sel $x MED00008154
- LZP __
- $a Pubmed-20170103